Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PRGO
PRGO logo

PRGO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Perrigo Company PLC (PRGO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.710
1 Day change
-0.09%
52 Week Range
28.430
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Perrigo Company PLC (PRGO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive insider buying trends, the company's financial performance has been weak, with declining revenue and significant net income losses. Additionally, the stock's technical indicators and options data do not suggest a strong upward momentum. It is better to hold off on investing until there are clearer signs of recovery or growth.

Technical Analysis

The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 60.838, showing no clear overbought or oversold condition. Moving averages are converging, suggesting indecision in price direction. Key support levels are at 10.701 and 10.293, while resistance levels are at 12.023 and 12.431. The stock is trading near its pivot level of 11.362, indicating a lack of strong directional movement.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market. However, implied volatility is high at 83.21 with a 96th percentile rank, suggesting significant uncertainty and potential price swings.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
5

Positive Catalysts

  • Insiders are buying, with a 107.21% increase in buying activity over the last month. The company has reported share gains in private label store brands and key branded businesses despite challenges in the infant nutrition sector.

Neutral/Negative Catalysts

  • Revenue dropped by 2.52% YoY in Q4 2025, and net income remains significantly negative at -1.418 billion. Analysts have lowered price targets, citing challenges in the infant nutrition business. The stock has a 30% chance of declining by -8.19% in the next month based on similar candlestick patterns.

Financial Performance

In Q4 2025, revenue declined by 2.52% YoY to $1.1096 billion. Net income increased significantly to -$1.418 billion, up 3086.74% YoY, but remains negative. EPS improved to -10.31, up 3121.88% YoY, but still negative. Gross margin dropped to 32.64%, down 3.72% YoY, reflecting weaker profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

JPMorgan lowered the price target from $18 to $15 and maintains a Neutral rating. Canaccord lowered the price target from $20 to $17 but maintains a Buy rating, citing challenges in the infant nutrition business but strength in other areas of the business.

Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
Wall Street analysts forecast PRGO stock price to rise
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 11.720
sliders
Low
18
Averages
20.33
High
23
Current: 11.720
sliders
Low
18
Averages
20.33
High
23
JPMorgan
Neutral
downgrade
$18 -> $15
AI Analysis
2026-02-27
Reason
JPMorgan
Price Target
$18 -> $15
AI Analysis
2026-02-27
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Perrigo to $15 from $18 and keeps a Neutral rating on the shares.
Canaccord
Susan Anderson
Buy
downgrade
$20 -> $17
2026-02-27
Reason
Canaccord
Susan Anderson
Price Target
$20 -> $17
2026-02-27
downgrade
Buy
Reason
Canaccord analyst Susan Anderson lowered the firm's price target on Perrigo to $17 from $20 and keeps a Buy rating on the shares. The firm said Management noted they ended 4Q25 and FY25 with share gains for both private label store brands and their key branded business, but saw softness in the infant nutrition business. It's been a challenging 2 years for the company primarily due to issues around the infant nutrition business. However, the rest of the business is performing well with distribution, contract, and share gains in a tough environment.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PRGO
Unlock Now

People Also Watch